The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...
ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.
AstraZeneca (NYSE: AZN) announced the US availability of Zegfrovy (sunvozertinib), a treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth ...
Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of EGFR-mutated lung cancer ...
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can ...
One of the most representative products from Hengrui Pharma's ADC research and development platform, trastuzumab rezetecan is being developed for more than ten indications, including breast, lung, ...
Hengrui Pharma presents Phase 3 ruzaltatug data at ESMO 2026, showing progression-free survival endpoint met in EGFR-mutated ...
Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while ...
A computational and synthesis study prioritized benzohydrazide compounds 3d and 3f for experimental EGFR testing, while the lack of biological assays means their binding and anticancer activity remain ...
In the ALK-rearranged NCI-H3122 model, ATNM-400 plus crizotinib achieved 97% TGI, compared with 50% for ATNM-400, 55% for crizotinib and 26% for patritumab deruxtecan alone. ATNM-400-containing ...
A new review in Genes & Diseases outlines how co-targeting EGFR alongside other tumor-driving molecules, delivered via ...
FURTHER shows firmonertinib 240 mg achieved 68% ORR and 16-month PFS in advanced EGFR PACC-mutant NSCLC, with intracranial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results